- Max Healthcare’s net income for the fourth quarter was 2.52 billion rupees, which is a slight increase of 0.4% from the previous year.
- The company recorded a revenue of 14.2 billion rupees, showing a hike of 17% on a year-to-year basis.
- Total costs for the period escalated by 18% year-on-year, standing at 11.3 billion rupees.
- The dividend per share was reported to be 1.50 rupees.
- The healthcare firm planned to construct a new 525-bed hospital in Gurugram.
- A substantial investment of INR 10.4 billion has been approved for this new venture in Gurugram.
- The board has given the go-ahead for a capacity expansion worth INR 3.8 billion at the Mohali hospital.
- An overview of opinions from the market shows 14 buys, 2 holds and 2 sells for Max Healthcare shares.
- The information compared to past results is based on values reported by the company’s original disclosures.
Max Healthcare Institute on Smartkarma
Analysts on Smartkarma are buzzing about Max Healthcare Institute‘s latest move into Lucknow, as highlighted by Tina Banerjee‘s report titled “Max Healthcare (MAXHEALTH IN): New Hospital Acquisition Expands Footfall in a New Populus City.” The report dives into Max Healthcare’s acquisition of Sahara Hospital, a 550-bed facility for approximately INR 9.4 billion. With an impressive track record of serving around 200,000 patients annually and generating a revenue run rate of INR 2 billion by FY24, Sahara Hospital is projected to be a strategic addition to Max Healthcare’s portfolio. The acquisition not only enhances Max Healthcare’s presence in a key city but also presents opportunities for expanding medical specialties like neurosciences, oncology, transplants, and robotics.
A look at Max Healthcare Institute Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
From the Smartkarma Smart Scores, Max Healthcare Institute shows a promising long-term outlook. With a strong emphasis on growth, resilience, and momentum, the company is positioned for future success. The high growth score suggests that the company is poised for expansion and development in the healthcare industry. Additionally, its resilience and momentum scores indicate a stable and upward trajectory, making it a potentially lucrative investment. While the value and dividend scores are moderate, the focus on growth and continuous momentum bodes well for Max Healthcare Institute‘s future performance.
Max Healthcare Institute Limited, known for its chain of hospitals in India, offers a wide range of specialized medical services to its patients. With a diverse portfolio including oncology, orthopaedics, eye care, and more, the company caters to various healthcare needs. This extensive service offering positions Max Healthcare Institute as a prominent player in the healthcare sector. Given its strong focus on growth, resilience, and momentum, investors may find Max Healthcare Institute a compelling choice for long-term investment opportunities.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
